Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 335-343

  Khademi, Mohsen ^a   Kockum, Ingrid ^a   Andersson, Magnus L ^a   Iacobaeus, Ellen ^a   Brundin, Lou ^a   Sellebjerg, Finn ^b   Hillert, Jan ^a   Piehl, Fredrik ^a   Olsson, Tomas ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Mental Health Services CPH   (Denmark)

Author keywords

cerebrospinal fluid; CXCL13; prognostic biomarker; relapsing remitting multiple sclerosis

Indexed keywords

BIOLOGICAL MARKER; CXCL13 CHEMOKINE; OLIGOCLONAL BAND;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LESIONS AND DEFECTS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTEIN BLOOD LEVEL; VALIDATION PROCESS; VIRUS INFECTION;

EID: 79953179371     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510389102     Document Type: Article

References (29)

1. Compston A. and Coles A. Multiple sclerosis. Lancet 2002 ; 359: 1221-1231. (Pubitemid 34304266)
2. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502-1517.
3. Daumer M., Neuhaus A., Herbert J. and Ebers G. Prognosis of the individual course of disease: The elements of time, heterogeneity and precision. J Neurol Sci 2009 ; 287 (Suppl 1). S50 - S55.
4. Salzer J., Svenningsson A. and Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010 ; 16: 287-292.
5. Norgren N., Rosengren L. and Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003 ; 987: 25-31. (Pubitemid 37267883)
6. Steinman L. The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease. Adv Immunol 1991 ; 49: 357-379.
7. Bielekova B. and Martin R. Development of biomarkers in multiple sclerosis. Brain 2004 ; 127: 1463-1478. (Pubitemid 38899400)
8. Martin R., Bielekova B., Hohlfeld R. and Utz U. Biomarkers in multiple sclerosis. Dis Markers 2006 ; 22: 183-185. (Pubitemid 44763271)
9. Link H. and Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977 ; 37: 397-401. (Pubitemid 8387873)
10. Archelos JJ, Storch MK and Hartung HP The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol 2000 ; 47: 694-706. (Pubitemid 30390190)
11. Kuenz B., Lutterotti A., Ehling R., et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS One 2008 ; 3: e2559.
12. Hauser SL, Waubant E., Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 ; 358: 676-688. (Pubitemid 351240747)
13. Lucchinetti CF, Gavrilova RH, Metz I., et al. Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 2008 ; 131: 1759-1775. (Pubitemid 351957454)
14. Ransohoff RM, Kivisakk P. and Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003 ; 3: 569-581. (Pubitemid 37328676)
15. Sorensen TL, Roed H. and Sellebjerg F. Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis. J Neuroimmunol 2002 ; 122: 125-131. (Pubitemid 34075498)
16. Krumbholz M., Theil D., Cepok S., et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006 ; 129: 200-211. (Pubitemid 43063771)
17. Sellebjerg F., Bornsen L., Khademi M., et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009 ; 73: 2003-2010.
18. Vissers JL, Hartgers FC, Lindhout E., Figdor CG and Adema GJ BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol 2001 ; 31: 1544-1549. (Pubitemid 32454703)
19. Narayan K., Dail D., Li L., et al. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol 2005 ; 57: 813-823. (Pubitemid 40798619)
20. Rupprecht TA, Pfister HW, Angele B., Kastenbauer S., Wilske B. and Koedel U. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 2005 ; 65: 448-450. (Pubitemid 41099810)
21. Ljostad U. and Mygland A. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 2008 ; 255: 732-737.
22. Rupprecht TA, Kirschning CJ, Popp B., et al. Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2. Infect Immun 2007 ; 75: 4351-4356. (Pubitemid 47378092)
23. Festa ED, Hankiewicz K., Kim S., et al. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler 2009 ; 15: 1271-1279.
24. Brettschneider J., Czerwoniak A., Senel M., et al. The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 2010 ; 5: e11986.
25. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001 ; 50: 121-127.
26. Iacobaeus E., Ryschkewitsch C., Gravell M., et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 2009 ; 15: 28-35.
27. Rudick RA, Cookfair DL, Simonian NA, et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999 ; 93: 8-14. (Pubitemid 29051546)
28. Miller DH, Weinshenker BG, Filippi M., et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008 ; 14: 1157-1174.
29. Piccio L., Naismith RT, Trinkaus K., et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010 ; 67: 707-714.